NOS2 and breast cancer: Doxorubicin is routinely used for breast cancer treatment in patients as a chemotherapeutic agent, and mechanistically reduces expression of MDSC-associated genes including Arg1, iNOS, S100A8 and S100A9 in breast tumour mouse models [45].